

## **Africa Contraceptive Drugs and Devices Market Report and Forecast 2024-2032**

Market Report (7 days) | 2024-02-13 | 160 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$4599.00
- Five User License \$6599.00
- Corporate License \$8599.00

### **Report description:**

Africa Contraceptive Drugs and Devices Market Report and Forecast 2024-2032

Africa Contraceptive Drugs and Devices Market Outlook

The Africa contraceptive drugs and devices market size is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032, driven by trend towards the use of long-acting reversible contraceptives (LARCs) like IUDs and contraceptive implants across the region.

Contraceptive Drugs and Devices: Introduction

Contraceptive drugs and devices are methods used to prevent pregnancy. Contraceptive drugs, such as birth control pills, patches, and injections, typically use hormones to inhibit ovulation or alter cervical mucus. Devices, like condoms, diaphragms, intrauterine devices (IUDs), and contraceptive implants, create physical or chemical barriers to prevent sperm from reaching an egg. These methods vary in form, effectiveness, and duration of action, offering individuals options to choose based on their health, convenience, and family planning goals.

Key Trends in the Africa Contraceptive Drugs and Devices Market

There's a noticeable trend towards the use of Long-Acting Reversible Contraceptives (LARCs) like IUDs and contraceptive implants. These methods are gaining popularity due to their efficacy, ease of use, and long duration, reducing the need for frequent administration or user compliance.

The market is witnessing significant technological advancements and innovation in contraceptive products. This includes the development of contraceptives with fewer side effects, non-hormonal options, and user-friendly designs. There's also a focus on developing digital platforms and mobile applications for education, reminders, and tracking fertility, enhancing user engagement and compliance.

There's a global push to increase awareness of contraceptive options and sexual health education, particularly in emerging economies. Governments and non-profit organizations are working to improve accessibility and affordability of contraceptive drugs and devices, aiming to reduce the incidence of unintended pregnancies and support family planning initiatives.

The market is observing a shift towards personalized contraception, where individuals choose methods based on their lifestyle, health status, and future fertility intentions. Healthcare providers are focusing more on personalized consultations and offering a broader range of contraceptive options to meet individual needs.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Regulatory policies and ethical considerations continue to shape the contraceptive drugs and devices market. Changes in healthcare policies, funding for family planning services, and product approvals have significant impacts on market dynamics. There's also an ongoing dialogue about reproductive rights and access to contraception, influencing public perception and the adoption of contraceptive methods.

#### Africa Contraceptive Drugs and Devices Market Segmentation

##### Market Breakup by Product

- Drugs
  - o□Oral Contraceptive Pills
  - o□Injectable Contraceptives
  - o□Topical Contraceptives
- Devices
  - o□Condoms
  - o□Diaphragms
  - o□Cervical Caps
  - o□Sponges
  - o□Vaginal Ring
  - o□Intra Uterine Devices (IUD)
  - o□Others
- Others

##### Market Breakup by Gender

- Male
- Female

##### Market Breakup by Distribution Channel

- Hospital Pharmacy
- Retail Pharmacy
- Clinics
- Online Channel
- Public Channel and NGOs
- Others

#### Africa Contraceptive Drugs and Devices Market Overview

In Africa, the contraceptive drugs and devices market is evolving, influenced by increasing awareness of family planning and reproductive health. Efforts by governments and international organizations to promote sexual and reproductive health education are driving the demand for contraceptive solutions. The market shows a preference for long-acting reversible contraceptives (LARCs) like implants and IUDs, due to their efficacy and longer duration of action. However, challenges such as cultural attitudes, access to healthcare services, and affordability impact the adoption of contraceptive methods. Initiatives aimed at improving healthcare infrastructure, reducing the cost of contraceptives, and empowering women through education are key factors shaping the market's growth in the region.

#### Africa Contraceptive Drugs and Devices Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

- Merck & Co. Inc.
- Mylan N.V.
- Pfizer Inc.
- Bayer AG
- AbbVie
- Lupin Limited
- Teva Pharmaceutical Industries Ltd

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

-[]Medicines360  
-[]Durex  
-[]Mankind Pharma  
-[]Johnson & Johnson  
-[]Gabler Medical  
-[]Sinapi Biomedical  
-[]Church & Dwight  
-[]CooperSurgical

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

## Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Africa Contraceptive Drugs and Devices Market Overview
  - 3.1 Africa Contraceptive Drugs and Devices Market Historical Value (2017-2023)
  - 3.2 Africa Contraceptive Drugs and Devices Market Forecast Value (2024-2032)
- 4 Africa Contraceptive Drugs and Devices Market Landscape
  - 4.1 Africa Contraceptive Drugs and Devices Developers Landscape
    - 4.1.1 Analysis by Year of Establishment
    - 4.1.2 Analysis by Company Size
  - 4.2 Africa Contraceptive Drugs and Devices Product Landscape
    - 4.2.1 Analysis by Product
    - 4.2.2 Analysis by Gender
- 5 Africa Contraceptive Drugs and Devices Market Dynamics
  - 5.1 Market Drivers and Constraints
  - 5.2 SWOT Analysis
  - 5.3 Porter's Five Forces Model
  - 5.4 Key Demand Indicators
  - 5.5 Key Price Indicators
  - 5.6 Industry Events, Initiatives, and Trends
  - 5.7 Value Chain Analysis
- 6 Africa Contraceptive Drugs and Devices Market Segmentation
  - 6.1 Africa Contraceptive Drugs and Devices Market by Product
    - 6.1.1 Market Overview
    - 6.1.2 Drugs
      - 6.1.2.1 Oral Contraceptive Pills
      - 6.1.2.2 Injectable Contraceptives
      - 6.1.2.3 Topical Contraceptives
    - 6.1.3 Devices
      - 6.1.3.1 Condoms

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.1.3.2 Diaphragms
- 6.1.3.3 Cervical Caps
- 6.1.3.4 Sponges
- 6.1.3.5 Vaginal Ring
- 6.1.3.6 Intra Uterine Devices (IUD)
- 6.1.3.7 Others
- 6.1.4 Others
- 6.2 Africa Contraceptive Drugs and Devices Market by Gender
  - 6.2.1 Market Overview
  - 6.2.2 Male
  - 6.2.3 Female
- 6.3 Africa Contraceptive Drugs and Devices Market by Distribution Channel
  - 6.3.1 Market Overview
  - 6.3.2 Hospital Pharmacy
  - 6.3.3 Retail Pharmacy
  - 6.3.4 Clinics
  - 6.3.5 Online Channel
  - 6.3.6 Public Channel and NGOs
  - 6.3.7 Others
- 7 Patent Analysis
  - 7.1 Analysis by Type of Patent
  - 7.2 Analysis by Publication year
  - 7.3 Analysis by Issuing Authority
  - 7.4 Analysis by Patent Age
  - 7.5 Analysis by CPC Analysis
  - 7.6 Analysis by Patent Valuation
  - 7.7 Analysis by Key Players
- 8 Grants Analysis
  - 8.1 Analysis by year
  - 8.2 Analysis by Amount Awarded
  - 8.3 Analysis by Issuing Authority
  - 8.4 Analysis by Grant Application
  - 8.5 Analysis by Funding Institute
  - 8.6 Analysis by NIH Departments
  - 8.7 Analysis by Recipient Organization
- 9 Clinical Trials Analysis
  - 9.1 Analysis by Trial Registration Year
  - 9.2 Analysis by Trial Status
  - 9.3 Analysis by Trial Phase
  - 9.4 Analysis by Therapeutic Area
  - 9.5 Analysis by Geography
- 10 Funding & Investment Analysis
  - 10.1 Analysis by Funding Instances
  - 10.2 Analysis by Type of Funding
  - 10.3 Analysis by Funding Amount
  - 10.4 Analysis by Leading Players
  - 10.5 Analysis by Leading Investors

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.6 Analysis by Geography
- 11 Partnership and Collaborations Analysis
  - 11.1 Analysis by Partnership Instances
  - 11.2 Analysis by Type of Partnership
  - 11.3 Analysis by Leading Players
  - 11.4 Analysis by Geography
- 12 Regulatory Framework
- 13 Supplier Landscape
  - 13.1 Merck & Co. Inc.
    - 13.1.1 Financial Analysis
    - 13.1.2 Product Portfolio
    - 13.1.3 Demographic Reach and Achievements
    - 13.1.4 Mergers and Acquisitions
    - 13.1.5 Certifications
  - 13.2 Mylan N.V.
    - 13.2.1 Financial Analysis
    - 13.2.2 Product Portfolio
    - 13.2.3 Demographic Reach and Achievements
    - 13.2.4 Mergers and Acquisitions
    - 13.2.5 Certifications
  - 13.3 Pfizer Inc.
    - 13.3.1 Financial Analysis
    - 13.3.2 Product Portfolio
    - 13.3.3 Demographic Reach and Achievements
    - 13.3.4 Mergers and Acquisitions
    - 13.3.5 Certifications
  - 13.4 Bayer AG
    - 13.4.1 Financial Analysis
    - 13.4.2 Financial Portfolio
    - 13.4.3 Demographic Reach and Achievements
    - 13.4.4 Mergers and Acquisitions
    - 13.4.5 Certifications
  - 13.5 AbbVie
    - 13.5.1 Financial Analysis
    - 13.5.2 Product Portfolio
    - 13.5.3 Demographic Reach and Achievements
    - 13.5.4 Mergers and Acquisitions
    - 13.5.5 Certifications
  - 13.6 Lupin Limited
    - 13.6.1 Financial Analysis
    - 13.6.2 Product Portfolio
    - 13.6.3 Demographic Reach and Achievements
    - 13.6.4 Mergers and Acquisitions
    - 13.6.5 Certifications
  - 13.7 Teva Pharmaceutical Industries Ltd
    - 13.7.1 Financial Analysis
    - 13.7.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.7.3 Demographic Reach and Achievements
- 13.7.4 Mergers and Acquisitions
- 13.7.5 Certifications
- 13.8 Medicines360
  - 13.8.1 Financial Analysis
  - 13.8.2 Product Portfolio
  - 13.8.3 Demographic Reach and Achievements
  - 13.8.4 Mergers and Acquisitions
  - 13.8.5 Certifications
- 13.9 Durex
  - 13.9.1 Financial Analysis
  - 13.9.2 Product Portfolio
  - 13.9.3 Demographic Reach and Achievements
  - 13.9.4 Mergers and Acquisitions
  - 13.9.5 Certifications
- 13.10 Mankind Pharma
  - 13.10.1 Financial Analysis
  - 13.10.2 Product Portfolio
  - 13.10.3 Demographic Reach and Achievements
  - 13.10.4 Mergers and Acquisitions
  - 13.10.5 Certifications
- 13.11 Johnson & Johnson
  - 13.11.1 Financial Analysis
  - 13.11.2 Product Portfolio
  - 13.11.3 Demographic Reach and Achievements
  - 13.11.4 Mergers and Acquisitions
  - 13.11.5 Certifications
- 13.12 Gabler Medical
  - 13.12.1 Financial Analysis
  - 13.12.2 Product Portfolio
  - 13.12.3 Demographic Reach and Achievements
  - 13.12.4 Mergers and Acquisitions
  - 13.12.5 Certifications
- 13.13 Sinapi Biomedical
  - 13.13.1 Financial Analysis
  - 13.13.2 Product Portfolio
  - 13.13.3 Demographic Reach and Achievements
  - 13.13.4 Mergers and Acquisitions
  - 13.13.5 Certifications
- 13.14 Church & Dwight
  - 13.14.1 Financial Analysis
  - 13.14.2 Product Portfolio
  - 13.14.3 Demographic Reach and Achievements
  - 13.14.4 Mergers and Acquisitions
  - 13.14.5 Certifications
- 13.15 CooperSurgical
  - 13.15.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.15.2 Product Portfolio
- 13.15.3 Demographic Reach and Achievements
- 13.15.4 Mergers and Acquisitions
- 13.15.5 Certifications
- 14 Africa Contraceptive Drugs and Devices Market - Distribution Model (Additional Insight)
  - 14.1 Overview
  - 14.2 Potential Distributors
  - 14.3 Key Parameters for Distribution Partner Assessment
- 15 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 16 Company Competitiveness Analysis (Additional Insight)
  - 16.1 Very Small Companies
  - 16.2 Small Companies
  - 16.3 Mid-Sized Companies
  - 16.4 Large Companies
  - 16.5 Very Large Companies
- 17 Payment Methods (Additional Insight)
  - 17.1 Government Funded
  - 17.2 Private Insurance
  - 17.3 Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

## Africa Contraceptive Drugs and Devices Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-13 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$4599.00
	Five User License	\$6599.00
	Corporate License	\$8599.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-26"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com